Every Form 4 that Alignment Healthcare, Inc. (ALHC) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ALHC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ALHC filings page.
Alignment Healthcare, Inc. Chief Information Officer Robert L. Scavo reported selling 4,044 shares of common stock in open-market transactions to cover tax withholding obligations tied to vesting restricted stock units. The sales were not discretionary trades. After these transactions, he continues to hold 498,970 shares of Alignment Healthcare common stock directly.
Alignment Healthcare, Inc. president Dawn Christine Maroney reported selling a total of 29,113 shares of common stock on March 12, 2026 in open-market transactions. Footnotes state these shares were sold solely to cover tax withholding obligations tied to vesting restricted stock units and were not discretionary trades. After these sales, she continues to hold 963,702 shares of Alignment Healthcare common stock directly.
Alignment Healthcare, Inc. Chief Executive Officer John E. Kao reported selling a total of 48,899 shares of common stock in open-market transactions on March 12, 2026. The shares were sold at weighted-average prices of $17.476 and $16.9919 per share.
According to the disclosure, these sales were required to cover tax withholding obligations triggered by the vesting of restricted stock units and did not represent discretionary trading decisions by Mr. Kao. After the transactions, he held 1,519,480 shares directly.
The filing also reports 2,472,641 shares of common stock held indirectly through the JEK Trust, dated February 8, 2021, for which Mr. Kao serves as trustee, providing additional indirect economic exposure to Alignment Healthcare stock.
Alignment Healthcare, Inc. president Dawn Christine Maroney reported a Form 4 showing a bona fide gift of 4,200 shares of common stock to family members on March 10, 2026. The transaction carried no sale price, and she now directly holds 992,815 shares after the gift.
Alignment Healthcare, Inc. director and CEO John E. Kao reported an open-market sale of 180,000 shares of common stock at a weighted-average price of $18.1864 per share on March 10, 2026. The shares were held indirectly through the JEK Trust, where he serves as trustee. Following the sale, indirect holdings reported for the trust were 2,472,641 shares, and his direct holdings were 1,568,379 shares. The transaction was executed under a Rule 10b5-1 trading plan adopted on March 12, 2025.
Alignment Healthcare, Inc. reported that Chief Human Resources Officer Andreas P. Wagner sold 21,118 shares of common stock in an open-market transaction on March 4, 2026 at a weighted-average price of $18.6216 per share.
The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 21, 2025, with individual trade prices ranging from $18.47 to $18.89 per share. Following this transaction, Wagner directly owns 148,687 Alignment Healthcare shares.
Mansour Adnan R. reported acquisition or exercise transactions in this Form 4 filing.
Alignment Healthcare, Inc. reported that Chief Digital Officer Adnan R. Mansour received an equity grant in the form of 23,441 restricted stock units (RSUs), each representing one share of common stock at no purchase price.
The RSUs will vest in approximately equal installments on February 4, 2027, 2028 and 2029, as long as Mansour continues to serve the company on each vesting date. This award increases his directly held equity stake and further links his compensation to the company’s long-term stock performance.
Alignment Healthcare President Dawn Christine Maroney sold 30,000 shares of common stock in an open-market transaction. The sale on 2026-02-17 was executed under a Rule 10b5-1 trading plan adopted on 05/22/2025, at a weighted-average price of $20.633 per share. After this transaction, she directly holds 997,015 shares of Alignment Healthcare common stock.
Alignment Healthcare, Inc. Chief Human Resources Officer Andreas P. Wagner reported a sale of company common stock on a Form 4. On February 10, 2026, he sold 22,238 shares of common stock at $20.47 per share and held 169,805 shares afterward, all directly owned.
According to the footnote, these shares were sold solely to cover tax withholding obligations arising from the vesting of restricted share units. The filing states this was not a discretionary trade by the reporting person, indicating the sale was linked to equity compensation rather than an open-market portfolio decision.
Alignment Healthcare reported that JEK Trust, of which Chief Executive Officer and director John E. Kao is trustee, sold 180,000 shares of the company’s common stock on 02/10/2026 at a weighted-average price of $20.4853 per share under a Rule 10b5-1 trading plan adopted on 03/12/2025.
After this sale, 2,652,641 shares are held indirectly through JEK Trust and 1,568,379 shares are held directly. The sale price reflects multiple trades in a range from $20.23 to $20.66 per share.
Alignment Healthcare president Dawn Christine Maroney reported insider sales of company stock. On 01/15/2026, she sold 15,129 shares of common stock at a weighted-average price of $22.1875 per share and an additional 14,871 shares at a weighted-average price of $22.781 per share.
The filing states these transactions were made under a Rule 10b5-1 trading plan adopted on 05/22/2025. The prices reflect multiple trades, with per‑share prices ranging from $21.58 to $22.57 for the first group and $22.58 to $22.98 for the second. After these sales, Maroney directly owned 1,027,015 shares of Alignment Healthcare common stock.
Alignment Healthcare CEO share transactions: Shares associated with Chief Executive Officer and director John E. Kao, held indirectly through the JEK Trust for which he serves as trustee, were sold in two transactions on 01/12/2026 under a Rule 10b5-1 trading plan adopted on 03/12/2025. The trust sold 177,273 shares of common stock at a weighted-average price of $21.0997 per share and an additional 2,727 shares at a weighted-average price of $21.5665 per share, with individual trades occurring within the disclosed price ranges.
Following these sales, indirect holdings reported as held by the JEK Trust totaled 2,832,641 shares, and direct holdings reported in John Kao’s name totaled 1,568,379 shares of Alignment Healthcare common stock.
Alignment Healthcare president Dawn C. Maroney reported open-market sales of company common stock executed under a Rule 10b5-1 trading plan adopted on 05/22/2025. On December 12, 2025, she sold 16,681 shares at a weighted-average price of $20.0204 per share, leaving 1,780,556 shares directly owned. On December 15, 2025, she sold 113,319 shares at a weighted-average price of $20.0068 per share, and directly held 1,667,237 shares afterward. For each date, the weighted-average prices reflect multiple trades within narrow price ranges disclosed in the report.
General Atlantic (ALN HLTH), L.P., a 10% owner of Alignment Healthcare, Inc., reported an open market sale of 11,119,494 shares of common stock at $18.57 per share, settled on December 12, 2025.
After this transaction, it beneficially owned 13,476,585 shares of Alignment Healthcare common stock indirectly, with the structure involving multiple General Atlantic investment funds and shares and restricted stock units held by Nicholas Robbert Vorhoff and David C. Hodgson for the benefit of General Atlantic Service Company, L.P.
A group of reporting persons led by General Atlantic (ALN HLTH), L.P., which is identified as a director and 10% owner of Alignment Healthcare, Inc., reported a large open-market sale of the company’s common stock. On December 12, 2025, they sold 11,119,494 shares of common stock at a net price of $18.57 per share.
After this transaction, the group reports indirect beneficial ownership of 13,476,585 Alignment Healthcare shares. This includes 13,167,733 shares held directly by General Atlantic (ALN HLTH), L.P., plus additional shares and 18,710 restricted stock units for each of Nicholas Robbert Vorhoff and David C. Hodgson held for the benefit of General Atlantic Service Company, L.P. The reporting persons describe a multi-entity General Atlantic structure and state that each disclaims beneficial ownership beyond any pecuniary interest.
Alignment Healthcare, Inc. reported an insider transaction by Sebastian Burzacchi, its chief operating officer for the management services organization. On 12/10/2025, he sold 12,585 shares of Alignment Healthcare common stock at $19.26 per share. According to the explanation, this represents the number of shares required to be sold to cover tax withholding obligations in connection with the vesting of restricted stock units and does not represent a discretionary trade by the reporting person. After the sale, he beneficially owns 237,793 shares of Alignment Healthcare common stock held directly.
Alignment Healthcare, Inc. disclosed that Chief Executive Officer and director John E. Kao sold 180,000 shares of common stock on 12/10/2025. The sale was reported at a weighted-average price of $19.0179 per share, with individual trades executed between $18.84 and $19.46 under a Rule 10b5-1 trading plan adopted on 03/12/2025.
Following this transaction, Kao beneficially owns 2,346,726 shares indirectly through the JEK Trust, for which he serves as trustee, and 2,839,942 shares directly.
Alignment Healthcare (ALHC) reported an insider transaction by Director Joseph S. Konowiecki. On 11/11/2025, 4,832 shares of common stock were sold at $16.49. The filing states the sale was to satisfy tax withholding from the vesting of restricted stock units and was not a discretionary trade by the reporting person.
Following the transaction, the director beneficially owns 1,081,141 shares, held directly.
Alignment Healthcare (ALHC) — insider transaction: CEO and director John E. Kao, via the JEK Trust, sold 180,000 shares of common stock on 11/10/2025 at a weighted-average price of $16.3154. The sale was made under a Rule 10b5-1 trading plan adopted on 03/12/2025.
After the transaction, Mr. Kao beneficially owns 2,526,726 shares indirectly through the JEK Trust and 2,839,942 shares directly.
Alignment Healthcare (ALHC) director reports an open‑market sale. Joseph S. Konowiecki sold 25,000 shares of common stock on 10/28/2025 at a price of $18 per share (transaction code S(1)). Following the sale, he beneficially owns 1,085,973 shares, held directly.
The footnote indicates a Rule 10b5‑1 trading plan adopted on 03/05/2025 in connection with the sale. No derivative securities transactions were reported in this filing.
Alignment Healthcare (ALHC) CEO and director John E. Kao reported the sale of 180,000 shares of common stock on 10/10/2025 under a Rule 10b5-1 trading plan adopted on 03/12/2025.
The weighted-average sale price was $17.286, with individual trades ranging from $16.97 to $17.60. Following the transaction, beneficial ownership included 2,706,726 shares held indirectly by the JEK Trust and 2,839,942 shares held directly. A prior transfer on 09/25/2025 moved 1,693,626 shares from direct ownership to the JEK Trust.
Alignment Healthcare (ALHC) Chief Medical Officer Hyong (Ken) Kim reported two non-discretionary stock sales tied to restricted stock unit vesting and a pre-existing trading plan. On 10/08/2025 Mr. Kim sold 33,655 shares at $17.29 to cover tax withholding, leaving 413,712 shares prior to the second sale. On 10/09/2025 he sold 51,379 shares at $17.5713, leaving 362,333 shares beneficially owned after the transactions. The Form 4 notes a Rule 10b5-1 trading plan adopted on 03/14/2025, and the filings state these sales were not discretionary trades but routine tax-withholding dispositions tied to RSU vesting.